DNA damage is a novel response to sublytic complement C5b-9–induced injury in podocytes

Jeffrey W. Pippin, Raghu Durvasula, Arndt Petermann, Keiju Hiromura, William G. Couser, and Stuart J. Shankland

Department of Medicine, Division of Nephrology, University of Washington, Seattle, Washington, USA

In response to Ab-complement–mediated injury, podocytes can undergo lysis, apoptosis, or, when exposed to sublytic (<5% lysis) amounts of C5b-9, become activated. Following the insertion of sublytic quantities of C5b-9, there is an increase in signaling pathways and growth factor synthesis and release of proteases, oxidants, and other molecules. Despite an increase in DNA synthesis, however, sublytic C5b-9 is associated with a delay in G2/M phase progression in podocytes. Here we induced sublytic C5b-9 injury in vitro by exposing cultured rat podocytes or differentiated postmitotic mouse podocytes to Ab and a complement source; we also studied the passive Heymann nephritis model of experimental membranous nephropathy in rats. A major finding was that sublytic C5b-9–induced injury caused an increase in DNA damage in podocytes both in vitro and in vivo. This was associated with an increase in protein levels for p53, the CDK inhibitor p21, growth-arrest DNA damage-45 (GADD45), and the checkpoint kinases-1 and -2. Sublytic C5b-9 increased extracellular signal-regulated kinase-1 and -2 (ERK-1 and -2), and inhibiting ERK-1 and -2 reduced the increase in p21 and GADD45 and augmented the DNA damage response to sublytic C5b-9–induced injury. These results show that sublytic C5b-9 induces DNA damage in vitro and in vivo and may explain why podocyte proliferation is limited following immune-mediated injury.

Methods

Cells in culture

**Rat podocytes.** Rat visceral glomerular epithelial cells, also called podocytes, were established in culture as described previously (6). In certain experiments, quiescent rat podocytes were studied to more closely resemble the quiescent in vivo podocyte phenotype by depriving them of growth factors for 48 h. Quiescence was confirmed by FACS analysis and BrdU staining (11, 12). Podocytes were exposed to Ab and a complement source (described below), and DNA damage was measured (described below).

**Differentiated postmitotic mouse podocytes.** To ensure that the results obtained in rat podocytes also occurred in another species and in cells that better represent cells in vivo, we used well-characterized differentiated postmitotic mouse podocytes (obtained from Peter Mundel, Albert Einstein College of Medicine, New York, New York, USA), referred to as conditionally immortalized H-2Kb-tsA58 kidneys. To define the amounts of Ab and complement required without producing podocyte injury or lysis (defined as >5% lactate dehydrogenase release; see below). Serum was diluted to 8% and applied to cells sensitized with Ab and incubated for 1 h at 37°C to allow C5b-9 insertion. Cells were washed with serum-free media to remove unbound complement. To ensure that C5b-9 attack was not inducing significant cell lysis, lactate dehydrogenase (LDH) was measured in the supernatants using the invitro toxicology assay kit (Sigma-Aldrich, St. Louis, Missouri, USA) (15). Lysis was expressed as a percentage of the change in the absorbance of the media compared with changes in absorbance of the triton-lysed cells and the media (<5% LDH release was regarded as sublytic).

**Passive Heymann nephritis model**

To test the hypothesis that C5b-9 induced podocyte DNA damage in vivo, the passive Heymann nephritis (PHN) model of experimental membranous nephropathy was induced in male Sprague-Dawley rats (Simonsen Laboratories, Gilroy, California, USA) by intraperitoneal injection (5 ml/kg body weight) of sheep Ab to Fx1A prepared as described previously. Sprague-Dawley rats injected with normal sheep serum (5 ml/kg body weight) served as controls for the anti-Fx1A Ab. To confirm that our results were indeed C5b-9 dependent, PHN was also induced in PVG C- rats and in PVG C- rats. Control and PHN rats were sacrificed at 3, 5, and 30 days (n = 6 at each time point) for renal biopsies and glomerular isolation. Urine protein excretion prior to sacrifice was determined in control and PHN animals using the sulphosalicylic acid method (16).

**Measuring DNA damage in vitro and in vivo**

**In vitro.** Three methods were used to determine the presence of DNA damage in complement-stimulated podocytes in vitro. A DNA precipitation assay (17), single-cell gel electrophoresis assay, and apurinic-apyrimidinic (AP) site counting assay were used.

For the DNA precipitation assay, podocytes were plated into 24-well plates with 2 µCi of H-thymidine for every 1 ml of media. Podocytes were allowed to grow for 3–4 days to incorporate H-thymidine into the DNA. Following stimulation with Ab and C- or C- serum, podocytes were

**Notes:**

- The Journal of Clinical Investigation | March 2003 | Volume 111 | Number 6
- Downloaded from http://www.jci.org on July 17, 2017. https://doi.org/10.1172/JCI15645
incubated in media for 30 min to 24 h, then dissolved using a lysis buffer. KCl (12 M) was added to lysed cells and incubated at 65°C for 10 min, iced for 5 min, then centrifuged at 3,200 g to separate precipitated chromatin DNA from damaged DNA (supernatant). Supernatants and DNA pellets were dissolved in scintillation fluid and counted in a Beckman 3500 scintillation counter. The percentage of single-stranded DNA (ssDNA) was calculated by dividing the counts per minute in the supernatant by the counts per minute in the supernatant plus the counts per minute in the pellet, and multiplying by 100.

The single-cell gel electrophoresis assay, or the comet assay (Trevigen, Gaithersburg, Maryland, USA) was also used. Podocytes were scraped 2 h after complement stimulation, diluted in low–melting point agarose, and applied to a microscope slide provided in the comet assay kit. Slides were incubated in lysis solution followed by an alkali solution to uncoil DNA. Slides were placed in a horizontal gel electrophoresis box, and 27 V was applied for 10 min. The ssDNA migrated away from the nucleus and were visualized using a fluorescent DNA stain. Images of the nuclei with the characteristic “tail” of damaged DNA were captured under fluorescent microscopy.

AP site counting was performed using the DNA damage–quantification kit from Dojindo Molecular Technologies Inc. (Gaithersburg, Maryland, USA). DNA was isolated from C5b-9–stimulated and control podocytes using the DNeasy isolation kit (QIAGEN Inc., Valencia, California, USA). AP sites were detected in isolated DNA using an aldehyde-reactive probe reagent (ARP). After treating the DNA with ARP reagent, AP sites became tagged with biotin, and the DNA was bound to a microtiter plate along with ARP-tagged DNA standards. The sites were visualized using peroxidase streptavidin. The number of AP sites in the sample DNA were determined by comparing absorbance at 650 nm of sample DNA to the standard curve.

In vivo. The comet assay (see above) was performed on isolated glomeruli to determine if DNA damage was occurring in podocytes in vivo.

TUNEL assay and DNA fragmentation

The use of the TUNEL assay has been reported previously (18). The suicide track DNA ladder kit (Oncogene Research Products, Boston, Massachusetts, USA) was used to determine if characteristic DNA fragmentation of apoptosis occurred in complement-stimulated podocytes in vitro. UV irradiation (5,000 mJ) was used as a positive control. DNA was extracted and apoptotic DNA was separated from high-molecular-weight chromatin using the extraction buffer. The fragmented DNA was precipitated using Pellet Paint coprecipitant, according to the manufacturer’s protocol. DNA was then exposed to electrophoresis in an agarose gel containing ethidium bromide (0.5 μg/ml) at 50 V.

Immunostaining

Renal biopsies were fixed in either methyl Carnoy’s solution or formalin and embedded in paraffin. To ensure equal Ab binding in control and PHN rats, immunofluorescent staining was performed and quantitated for sheep IgG and C5b-9 (19). Indirect immunoperoxidase staining (20) was performed on 4-μm sections using the following primary Ab’s for overnight incubation: clone PAB421 mouse monoclonal to murine p53, sheep polyclonal anti–CHK-1, rabbit polyclonal anti–CHK-2 (Oncogene Research Products), rabbit polyclonal anti-GADD45 (Santa Cruz Biotechnology Inc., Santa Cruz, California, USA), clone SX118 mouse monoclonal to p21 (Pharmingen, San Diego, California, USA). Controls included omitting the primary Ab or substituting the primary Ab with preimmune serum. p53 immunostaining was performed on frozen sections by indirect immunofluorescent staining.

Western blot analysis

Western blot analysis was performed as described previously (12, 19, 21) on protein extracted from cultured mouse and rat podocytes exposed to sublytic C5b-9 attack and from isolated glomeruli from control and PHN rats. Protein extracts (20 μg) were separated under reduced conditions on a 15%, 12%, or 8% SDS-PAGE gel. Membranes were incubated with Ab’s to p21, p53, CHK-1, CHK-2, GADD45, and ERK-1 and -2 (Cell Signalling Technology, Beverly, Massachusetts, USA). Controls included using protein known to be positive or negative for the specific protein being stained or omitting the primary Ab. To ensure equal protein loading, Ab’s to the housekeeping proteins tubulin (RBI, Natick, Massachusetts, USA) or actin (Chemicon International, Temecula, California, USA) were used, and wherever phosphorylated proteins were measured, total protein for that product was also measured.

Inhibiting ERK-1 and -2

Because our results showed that ERK-1 and -2 was phosphorylated by sublytic C5b-9 injury (see below), in select experiments the activity of ERK-1 and -2 was selectively inhibited using U0126 (50 μM; Cell Signalling Technology). Finally, to determine the impact of inhibiting ERK-1 and -2 on DNA damage, DNA damage was measured (as described above) in cells exposed to U0126, following the induction of sublytic C5b-9.

Results

Exposing podocytes to Ab and complement induces sublytic attack

There was an increase in LDH of 4% in both mouse and rat podocytes exposed to Ab and a complement source (C+ serum) compared with control cells exposed to Ab and PVG-C6–deficient (C–) serum (data not shown). Similarly, there was an increase of 4% LDH release in RMCs exposed to anti-Thy1 Ab and C+ serum compared with control cells exposed to Ab and C– serum (data not shown). Thus, we induced sublysis (<5%) in mouse and rat podocytes and in RMCs.
Sublytic C5b-9 injury causes DNA damage in podocytes, but not mesangial cells, in vitro

DNA damage was measured by three methods. The results of the ssDNA damage assay is shown in Figure 1. Figure 1a shows that exposing proliferating rat podocytes to Ab and control C– serum was not associated with ssDNA damage. In contrast, there was a significant increase in ssDNA remaining after precipitation in proliferating rat podocytes exposed to Ab and a complement source (C+ serum) (P < 0.001). Figure 1b shows the DNA damage results in quiescent rat podocytes. Podocytes deprived of serum exited the cell cycle, measured by FACS analysis and BrdU staining (results not shown), similar to podocytes in vivo. Exposing quiescent podocytes to Ab and C+ serum caused a marked increase in DNA damage that was not detected in control quiescent podocytes exposed to Ab and control C– serum (P < 0.001). These data show that sublytic C5b-9 causes DNA damage in both proliferating and quiescent cultured rat podocytes. Figure 1c shows the results obtained in differentiated mouse podocytes. There was a significant increase in ssDNA damage in differentiated postmitotic mouse podocytes exposed to sublytic C5b-9 attack compared with controls.

Figure 2 shows results obtained using the comet assay. DNA damage was not detected in normal rat podocytes (Figure 2a) and control cells exposed to Ab and C–.

Figure 2
Comet assay. DNA damage was measured in rat (a–d) and mouse (e–h) podocytes in vitro using the comet assay. (a and e) DNA damage was not detected in normal podocytes not exposed to Ab or a complement source. (b and f) In podocytes exposed to Ab and complement, the characteristic “tail” of damaged DNA is seen migrating away from the nucleus. (c and g) In contrast, DNA damage was not detected in control cells exposed to Ab without a complement source. (d and h) In UV-irradiated cells, used as a positive control, DNA damage was detected. The comet assay was also performed on glomeruli isolated from control and PHN rats. (i–l) DNA damage was not detected in control rats injected with normal sheep serum (i) nor in PVG C– rats injected with anti-Fx1A Ab (k). DNA damage was detected in Sprague-Dawley PHN (j) and in PVG C+ (l) rats injected with anti-Fx1A Ab.
serum (Figure 2c). The comet assay was positive, however (“tail” of damaged DNA migrating away from the nucleus), in rat podocytes exposed to sublytic C5b-9 (Figure 2b) and in rat podocytes exposed to UV irradiation (Figure 2d) (positive control). The comet assay was negative in normal differentiated mouse podocytes (Figure 2e) and control mouse podocytes exposed to Ab and C− serum (Figure 2g). In contrast, exposing mouse podocytes to Ab and a complement source results in a tail (Figure 2f). Mouse podocytes exposed to UV irradiation also exhibited a tail (Figure 2h).

The number of AP sites in DNA from rat podocytes following sublytic C5b-9 exposure was also measured. Podocytes exposed to Ab and C+ serum contained twice the number of AP sites compared with podocytes exposed to Ab and C− serum (40 ± 1.3 versus 22 ± 4.8; \( P < 0.001 \)). Similar results were obtained using mouse podocytes. These results show that sublytic C5b-9 exposure causes DNA damage in mouse and rat podocytes in vitro.

We also measured DNA damage in RMCs following sublytic C5b-9 exposure. In contrast to podocytes, DNA damage was not detected in RMCs (data not shown). However, UV irradiation, used as a positive control, did induce DNA damage in RMCs (data not shown). Taken together, these results show that sublytic C5b-9 exposure induced DNA damage specifically in podocytes, but not in RMCs.

Sublytic C5b-9 does not induce apoptosis in podocytes

The results of the TUNEL and suicide track DNA ladder assays used to measure apoptosis are shown for rat (Figure 3, a–c) and mouse (Figure 3, d–f) podocytes. Exposing cultured rat and mouse podocytes to Ab without a complement source did not induce apoptosis (Figure 3, a and d). In addition, Figures 3, b and e, show that exposing podocytes to Ab and a complement source was not associated with positive TUNEL staining. The results were not false negatives, because TUNEL staining increased in podocytes exposed to apoptosis-inducing doses of UV irradiation (Figure 3, c and f).

The results of DNA laddering measured by the suicide track DNA ladder assay are shown in Figure 3. DNA laddering was not detected in rat (Figure 3g) or mouse (Figure 3h) podocytes exposed to Ab with or without a complement source. DNA laddering, however, was detected in podocytes exposed to UV irradiation, which was used as a positive control. Taken together, these assays show that sublytic C5b-9–induced injury to rat and mouse podocytes does not cause apoptosis, but rather specifically causes DNA damage.

Figure 3

Sublytic C5b-9 does not induce apoptosis in podocytes. a–f show TUNEL staining, a marker of apoptosis. Apoptosis was not detected in control rat (a) and mouse (d) podocytes exposed to Ab without a complement source, nor in experimental rat (b) and mouse (e) cells exposed to Ab with a complement source. In contrast, TUNEL staining is increased in rat (c) and mouse (f) podocytes exposed to UV irradiation used as a positive control. The suicide track DNA ladder assay is shown in rat (g) and mouse (h) podocytes. In contrast to DNA fragmentation in podocytes exposed to UV irradiation (lanes 1, 2, 3), DNA fragmentation was not detected in cells exposed to Ab with (C+) (lanes 4, 5, 6) and without (C−) (lanes 7, 8, 9) a complement source.
Sublytic C5b-9 exposure also causes DNA damage in PHN rats

PHN was induced in Sprague-Dawley, PVG C+, and PVG C– rats. Immunostaining for sheep IgG was similar in all three strains injected with anti-Fx1A Ab (results not shown). In contrast, C5b-9 staining was not detected in Sprague-Dawley rats injected with normal sheep serum, nor in PVG C– rats injected with anti-Fx1A Ab (results not shown). As expected, there was a significant increase in proteinuria in Sprague-Dawley rats with PHN (165 ± 10.4 mg) compared with control Sprague-Dawley rats (14.6 ± 3.2) \((P < 0.001\) versus control).

DNA damage in vivo was measured in PHN rats by several methods. There was no detectable glomerular DNA damage in control animals (Figure 2i). In contrast, DNA damage was present in isolated glomeruli from PHN Sprague-Dawley rats (Figure 2j). To prove that DNA damage was a consequence of C5b-9, PHN was also induced in PVG C+ and PVG C– rats. Our data showed that DNA damage was not detected in control PVG C– animals injected with anti-Fx1A (results not shown). Taken together, these results show that p53 expression increases in vitro and in vivo following exposure to Ab and a complement source and that this effect was a consequence of C5b-9 formation.

Specific cell cycle proteins are increased in podocyte following C5b-9 attack

p53 levels increase in vitro and in vivo following sublytic C5b-9 attack

Figure 4 shows that p53 protein was detected in very low abundance in rat (Figure 4a) and mouse (Figure 4b) control podocytes in vitro exposed to Ab without a complement source. In contrast, Figure 4 shows that exposing rat (Figure 4a) and mouse (Figure 4b) podocytes to Ab and a complement source is associated with a marked increase in p53 protein levels.

We next determined if C5b-9 attack also increased p53 in vivo, using the PHN model. As shown in Figure 5, p53 immunostaining was not detected in control glomeruli (Figure 5a). In contrast, there was a marked increase in p53 immunostaining in PHN rats in a podocyte distribution (Figure 5b). Figure 5 also shows a Western blot analysis performed on protein extracted from isolated glomeruli and confirms that p53 protein levels were increased in glomeruli from PHN rats compared with control rats.

To confirm that the increase in p53 was due to C5b-9, we also examined p53 expression in PVG C+ and PVG C– rats injected with anti-Fx1A Ab. As expected, there was an increase in p53 levels measured by immunostaining and Western blot analysis in PHN PVG C+ rats, which was not detected in PVG C– animals injected with anti-Fx1A (results not shown). Taken together, these results show that p53 expression increases in vitro and in vivo following exposure to Ab and a complement source and that this effect was a consequence of C5b-9 formation.
The levels of p21 were also increased in PVG C+ rats with PHN measured by immunostaining in a typical podocyte distribution (results not shown). In contrast, p21 expression did not increase in PVG C– rats injected with anti-Fx1A Ab. These results show that C5b-9 increases p21 levels in vitro and in vivo.

**GADD45.** Figure 4 shows that GADD45 was detected at low levels in control rat (Figure 4a) and mouse (Figure 4b) podocytes and that levels increased in podocytes following sublytic C5b-9 attack. GADD45 protein was also increased in rats with PHN measured by Western blot analysis (Figure 5) and in PVG C+ rats with PHN (data not shown). The increase in GADD45 in PHN rats was also detected by immunostaining and the increase localized to podocytes (results not shown). In contrast, GADD45 levels did not increase in PVG C– rats injected with anti-Fx1A Ab. Taken together, the results show that C5b-9 increases GADD45.

**CHK-1 and CHK-2.** In rat and mouse podocytes, total CHK-1 and CHK-2 levels were in low abundance in control cells exposed to Ab without a complement source (Figure 4). In contrast, Figure 4 shows an increase in phosphorylated CHK-1 and CHK-2 in rat (Figure 4a) and mouse (Figure 4b) podocytes in vitro exposed to Ab and a complement source. The total levels of CHK-1, but not CHK-2, increased following sublytic C5b-9 injury in both rat and mouse podocytes (Figure 4a and b) Figure 4 also shows that the increase in total and phosphorylated proteins was not due to differences in protein loading, because there was no difference in the protein levels of the housekeeping proteins, tubulin and actin.

The levels of CHK-1 and CHK-2 were also examined in vivo on protein extracted from isolated glomeruli from PHN and control rats. Figure 5 shows that although total CHK-1 and CHK-2 were detected in control and PHN rats, phosphorylated CHK-1 and CHK-2 were not detected in control Sprague-Dawley rats and PVG C– (data not shown). CHK-1 (results not shown) and CHK-2 immunostaining were increased in Sprague-Dawley rats (Figure 5f) and PVG C+ (not shown) rats with PHN, in a typical podocyte distribution. Western blot analysis also showed an increase in phosphorylated CHK-1 and CHK-2 following C5b-9-induced exposure in vivo in PHN Sprague-Dawley rats (Figure 5) and PVG C+ (data not shown). Results show the phosphorylated (and biologically active) forms of CHK-1 and CHK-2 increase in podocytes in vitro and in vivo following complement attack, and this effect is a consequence of C5b-9 formation.

**Inhibiting ERK reduces DNA response genes and increases DNA damage**

Figure 6a shows the temporal expression of phosphorylated ERK-1 and -2, measured by Western blot analysis, following exposure of podocytes in vitro to sublytic C5b-9 attack. We measured ERK immediately (0–45 min) and later (1–20 h) after sublytic injury. There was a biphasic increase in phosphorylated ERK levels within 15 min and again at 8 h (Figure 6b). The increase was not due to unequal protein loading, because total ERK-1 and -2 levels were similar in all lanes, as was the housekeeping protein, actin (data not shown).

We next determined the role of ERK in the response to DNA damage induced by C5b-9. Figure 6c shows that inhibiting ERK with U0126 in C5b-9–attacked podocytes reduced the levels of p21 and GADD45 protein, but not p53. These results show that ERK regulates the expression of p21 and GADD45 following sublytic C5b-9–induced injury in podocytes.

Finally, we asked if ERK-1 and -2 was critical in the DNA-damage response to sublytic C5b-9 injury, and the results are shown in Figure 6d. Compared with podocytes undergoing sublytic C5b-9–induced injury, inhibiting ERK-1 and -2 significantly augmented DNA damage induced by C5b-9. These studies show that ERK-1 and -2 protects podocytes from C5b-9-induced injury DNA damage and that this effect is mediated through p21 and GADD45.

**Discussion**

Podocytes are the target of immune-mediated injury in glomerular diseases, particularly membranous nephropathy (22). Following sublytic C5b-9 insertion, podocytes increase the levels of growth factors,
cytokines, and extracellular matrix proteins, activate specific signaling pathways and transcription factors, and release proteases and oxidants (23). Sublytic C5b-9 induces podocyte activation in vitro and in vivo, and this is associated with cell-cycle entry and DNA synthesis (albeit limited) (6, 19). In contrast to RMCs (24), however, mitosis and cytokinesis are not marked in podocytes following C5b-9 injury (7, 9, 19). In this study we report the finding that sublytic C5b-9 causes DNA damage to podocytes in vitro and in vivo, which is associated with an increase in p53, GADD45, CHK-1 and CHK-2, and CDK-inhibitor p21 and that the MAPK, ERK-1 and -2 protects podocytes from DNA damage induced by C5b-9. The results show that DNA damage is another consequence of cell exposure to sublytic C5b-9 insertion into cell membranes.

In contrast to glomerular mesangial and endothelial cells, podocytes do not readily proliferate in response to immune-mediated injury. Moreover, the inadequate proliferative response by podocytes contributes to the development of glomerulosclerosis (8, 25). Proliferation is governed at the level of the cell cycle by cell cycle regulatory proteins (26). Podocytes have the nuclear machinery required for DNA synthesis (19). Sublytic C5b-9 attack on podocytes, however, causes a delay/inhibition in G2/M phase (6). Taken together, these studies suggest that the apparent lack of podocyte proliferation occurs both at the level of DNA synthesis and mitosis. Accordingly, the focus of this study was to determine possible mechanisms underlying podocyte G2/M phase arrest following C5b-9–induced injury.

The first major finding in the current study was that sublytic C5b-9–induced podocyte injury causes DNA damage in podocytes in vitro and in vivo. The results were similar in rat and differentiated postmitotic mouse podocytes. In contrast, sublytic C5b-9 did not cause DNA damage in RMCs. Moreover, DNA damage was also significantly increased in podocytes in the PHN model of membranous nephropathy, but not in control animals injected with normal sheep serum. Our in vitro and in vivo data show that the phenomenon of DNA damage is C5b-9 dependent. As will be discussed below, our results show that C5b-9 also increases specific DNA damage response genes, further supporting the notion that our findings are specific to DNA damage. In contrast to mesangial cells (27), sublytic C5b-9 injury did not induce apoptosis in cultured rat and mouse podocyte. One explanation is a dose effect, because more lytic concentrations of C5b-9 may have induced apoptosis.

Cells arrest in the cell cycle in order for adequate repair mechanisms to operate following DNA damage. A second major finding in the current study was that sublytic C5b-9–induced injury increased the levels of p53 in mouse and rat podocyte in vitro and in experimental membranous nephropathy in vivo. To date, an increase in p53 levels has only been described in response to injury induced by UV irradiation and certain DNA-damaging agents (28). We can now add sublytic DNA damage to the list of injuries increasing p53. The CDK inhibitor p21 inhibits cell cycle progression at G1/S and G2/M (29), and p21 is increased in podocytes in PHN rats (19). Podocyte proliferation is markedly increased in p21-null mice with immune-mediated glomerulonephritis (30). In this study we show that p21 is also increased in podocytes in culture, confirming our findings in vivo in response to sublytic C5b-9. Studies have shown that following DNA damage, p53-dependent increases in p21 are required to halt cell cycle progression to allow adequate time for DNA repair mechanisms (31). Accordingly, we speculate that the increase in p21 in C5b-9–injured podocytes in vitro and in vivo may be due to increased p53 expression as a consequence of DNA damage. Increased p21 in turn would inhibit podocyte proliferation at G1/S and G2/M phases.

GADD45 (growth arrest and DNA damage) is a family of genes that has been implicated in the cellular response to DNA damage (32). Our data showed that GADD45 is increased following sublytic injury in vitro and in vivo. Transcription of GADD45, at least partially, is induced by p53 in response to DNA damage induced by UV and ionizing radiation and other DNA-damaging agents. GADD45 binds to proliferating cell nuclear antigen at several residues, thereby causing cell cycle arrest, and GADD45 may also be involved in nuclear excision repair of damaged DNA (33, 34). GADD45 is usually expressed at low levels during the S-phase, but is rapidly induced in response to damaged DNA. Protein expression of GADD45 was increased in podocytes exposed in vitro to C5b-9, as well as in glomeruli from PHN rats.

Recent studies have shown that the G2/M phase is also inhibited by a family of proteins known as checkpoint kinase inhibitors (CHK-1 and CHK-2) (35). A third major finding in this study was that sublytic C5b-9–induced podocyte injury increased the levels of CHK-1 and CHK-2 in vitro and in podocytes in vivo in the PHN model. Of note, CHK-1 levels and activity are regulated in part by p53. These observations have lead us to suggest that the increase in p53 in the current study may also limit podocyte proliferation by increasing CHK protein levels.

ERK, a member of the MAP kinases, has been shown by Cybulsky et al. to increase in podocytes following sublytic C5b-9 injury (36). The fourth finding in the current study was that inhibiting ERK caused a marked decrease in p21 and GADD45. ERK has been shown to be involved in the signaling response to UV irradiation–induced DNA damage. Studies by Kraus have also shown an increase in phosphorylated ERK in COS and K562 cells in response to sublytic C5b-9 injury (37). Our results, however, showed that inhibiting ERK-1 and -2 augmented the DNA-damage response to sublytic C5b-9 in podocytes. Taken together, our data suggests that following sublytic C5b-9–induced injury, increased ERK activation protects podocytes from DNA damage by increasing p21 and GADD45.

In summary, to examine the possibility that C5b-9–induced podocyte injury may cause DNA damage, we
have used cultured podocytes and the PHN model of membranous nephropathy for our studies, because in this model Ab-complement–induced injury can be examined both in vitro and in vivo in circumstances that mimic the human disease membranous nephropathy. In PHN, IgG Ab to podocyte antigen(s) on the cell membrane binds exclusively to the podocyte and leads to C5b-9 insertion into the podocyte membrane and a consequent nonlytic form of injury that results in proteinuria. The PHN model is C5b-9 dependent and mediated by molecules such as oxidants (38) and pro- teases (39, 40) that are produced by podocytes in response to sublytic C5b-9 attack. The same system of Ab/C5b-9 attack can also be replicated with podocytes in vitro. By manipulating the presence or absence of C6 in these systems, the consequence of C5b-9 attack on podocytes may be examined, and the effect on cell cycle regulatory proteins and DNA damage response genes may be assessed. We conclude that a novel response to sublytic C5b-9 attack can also be replicated with podocytes in vitro. In the case of podocytes, DNA damage may explain in part the lack of proliferation in certain immune-mediated glomerular diseases.

Acknowledgments

This work was supported by Public Health Service grants (DK34198, DK52121, DK51096, DK56799), a George M. O’Brien Kidney Center grant (DK47659), and a Juvenile Diabetes Research Foundation Award (S.J. Shankland). S.J. Shankland holds an American Heart Association Established Investigator Award. We thank Peter Mundel for the use of mouse podocytes.